Can trehalose prevent neurodegeneration? insights from experimental studies

Current Drug Targets

Volumn 15, Issue 5, 2014, Pages 551-557

  Emanuele, Enzo ^a  

^a Living Research Sas   (Italy)

Author keywords

Alzheimer's disease; Autophagy; Huntington's disease; Neurodegeneration; Parkinson's disease; Trehalose

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; GLUCOSE; HUNTINGTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE; POLYGLUTAMINE; PRION PROTEIN; RAPAMYCIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; TREHALOSE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOPHAGY; CLINICAL PHARMACOLOGY; DRUG CLEARANCE; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERANCE; HUMAN; HUNTINGTON CHOREA; HYPOXIA; LD 50; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PARKINSON DISEASE; PATHOGENESIS; PHYSICAL CHEMISTRY; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SURVIVAL; TOXICOLOGY;

ANIMALS; AUTOPHAGY; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PROTEIN STABILITY; TREHALOSE;

EID: 84898605672     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140225104705     Document Type: Article

References (75)

1. Checkoway H, Lundin JI, Kelada SN. Neurodegenerative diseases. IARC Sci Publ 2011; 163: 407-419.
2. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neuro-sci 2003; 26: 81-104.
3. Geldenhuys WJ, Van der Schyf CJ. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr Med Chem 2013; 20: 1662-1672.
4. Geldenhuys WJ, Van der Schyf CJ. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov 2013; 8: 115-129.
5. Hampel H, Lista S. Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging 2013; 17: 54-63.
6. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neu-rodegenerative diseases. Biochem Pharmacol 2006; 72: 1197-1206.
7. Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeor-giou GM. Protein misfolding in neurodegenerative diseases. Neu-ropathol Appl Neurobiol 2004; 30: 2152-24.
8. Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol 2008; 65: 184-189.
9. Naeem A, Fazili NA. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins. Cell Biochem Biophys 2011; 61: 237-250.
10. Mulligan VK, Chakrabartty A. Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis. Proteins 2013; 81: 1285-1303.
11. Nakamura T, Lipton SA. Cell death: protein misfolding and neu- rodegenerative diseases. Apoptosis 2009; 14: 455-468.
12. Kaushik JK, Bhat R. Why is trehalose an exceptional protein stabilizer? An analysis of the thermal stability of proteins in the presence of the compatible osmolytetrehalose. J Biol Chem 2003; 278: 26458-26465.
13. Jain NK, Roy I. Effect of trehalose on protein structure. Protein Sci 2009; 18: 24-36.
14. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007; 282: 5641-5652.
15. Richards AB, Krakowka S, Dexter LB, et al. Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies. Food Chem Toxicol 2002; 40: 871-898.
16. Chen Q, Haddad GG. Role of trehalose phosphate synthase and trehalose during hypoxia: from flies to mammals. J Exp Biol 2004; 207: 3125-3129.
17. Muller YL, Hanson RL, Knowler WC, et al. Identification of genetic variation that determines human trehalase activity and its association with type 2 diabetes. Hum Genet 2013; 132: 697-707.
18. Bergoz R, Vallotton MC, Loizeau E. Trehalase deficiency. Prevalence and relation to single-cell protein food. Ann Nutr Metab 1982; 26: 291-295.
19. van Can JG, van Loon LJ, Brouns F, Blaak EE. Reduced glycaemic and insulinaemic responses following trehalose and isomaltulose ingestion: implications for postprandial substrate use in impaired glucose-tolerant subjects. Br J Nutr 2012; 108: 1210-1217.
20. Iordachescu M, Imai R. Trehalose biosynthesis in response to abiotic stresses. J Integr Plant Biol 2008; 50: 1223-1229.
21. Elbein AD, Pan YT, Pastuszak I, Carroll D. New insights on trehalose: a multifunctional molecule. Glycobiology 2003; 13: 17R-27R.
22. Crowe JH. Trehalose as a chemical chaperone: fact and fantasy. Adv Exp Med Biol 2007; 594: 143-158.
23. Singer MA, Lindquist S. Multiple effects of trehalose on protein folding in vitro and in vivo. Mol Cell 1998; 1: 639-648.
24. Benaroudj N, Lee DH, Goldberg AL. Trehalose accumulation during cellular stress protects cells and cellular proteins from damage by oxygen radicals. J Biol Chem 2001; 276: 24261-24267.
25. Gandhi S, Abramov AY. Mechanism of oxidative stress in neu-rodegeneration. Oxid Med Cell Longev 2012; 2012: 428010.
26. Chen Q, Behar KL, Xu T, Fan C, Haddad GG. Expression of Dro-sophila trehalose-phosphate synthase in HEK-293 cells increases hypoxia tolerance. J Biol Chem 2003; 278: 49113-4118.
27. Minutoli L, Altavilla D, Bitto A, et al. Trehalose: a biophysics approach to modulate the inflammatory response during endotoxic shock. Eur J Pharmacol 2008; 589: 272-80.
28. Aktan F. Inos-mediated nitric oxide production and its regulation. Life Sci 2004; 75: 639-53.
29. Echigo R, Shimohata N, Karatsu K, et al. Trehalose treatment suppresses inflammation, oxidative stress, and vasospasm induced by experimental subarachnoid hemorrhage. J Transl Med 2012; 10: 80.
30. Meng Y, Yong Y, Yang G, et al. Autophagy alleviates neurode-generation caused by mild impairment of oxidative metabolism. J Neurochem 2013; 126: 805-818.
31. Metcalf DJ, García-Arencibia M, Hochfeld WE, Rubinsztein DC. Autophagy and misfolded proteins in neurodegeneration. Exp Neurol 2012; 238: 22-28.
32. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007; 6: 352-361.
33. Bové J, Martínez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 2011; 12: 437-452.
34. Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 2008; 32: 16-25.
35. Masters CL, Selkoe DJ. Biochemistry of amyloid p-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006262.
36. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 2013; 126: 479-497.
37. Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis 2005; 20: 74-81.
38. Liu FF, Ji L, Dong XY, Sun Y. Molecular insight into the inhibition effect of trehalose on the nucleation and elongation of amyloid beta-peptide oligomers. J Phys Chem B 2009; 113: 11320-11329.
39. Reddy AS, Izmitli A, de Pablo JJ. Effect of trehalose on amyloid beta (29-40)-membrane interaction. J Chem Phys 2009; 131: 085101.
40. Izmitli A, Schebor C, McGovern MP, Reddy AS, Abbott NL, de Pablo JJ.Effect of trehalose on the interaction of Alzheimer's Ap-peptide and anionic lipid monolayers. Biochim Biophys Acta 2011; 1808: 26-33.
41. Perucho J, Casarejos MJ, Gomez A, Solano RM, de Yébenes JG, Mena MA. Trehalose protects from aggravation of amyloid pathology induced by isoflurane anesthesia in APP(swe) mutant mice. Curr Alzheimer Res 2012; 9: 334-343.
42. Du J, Liang Y, Xu F, Sun B, Wang Z. Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice. J Pharm Pharmacol 2013; 65: 1753-1756.
43. Huang HC, Jiang ZF. Accumulated amyloid-beta peptide and hy-perphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis 2009; 16: 15-27.
44. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 2012; 135: 2169-2177.
45. deLau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-535.
46. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 2011; 6: 193-222.
47. Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J Neurol 2003; 250 Suppl 3: 311-314.
48. Yu WB, Jiang T, Lan DM, et al. Trehalose inhibits fibrillation of A53T mutant alpha-synuclein and disaggregates existing fibrils. Arch Biochem Biophys 2012; 523: 144-150.
49. Lan DM, Liu FT, Zhao J, et al. Effect of trehalose on PC 12 cells overexpressing wild-type or A53T mutant a-synuclein. Neurochem Res 2012; 37: 2025-2032.
50. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012; 2012: 845618.
51. Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis 2010; 5: 40.
52. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
53. Ramaswamy S, McBride JL, Kordower JH. Animal models of Huntington's disease. ILAR J 2007; 48: 356-373.
54. Tanaka M, Machida Y, Niu S, et al. Trehalose alleviates polyglu-tamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10: 148-154.
55. Yang CR, Yu RK. Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J Neurosci Res 2009; 87: 26-33.
56. Chaudhary RK, Kardani J, Singh K, Banerjee R, Roy I. Deciphering the roles of trehalose and Hsp104 in the inhibition of aggregation of mutant huntingtinin a yeast model of Huntington's disease. Neuromolecular Med 2013 Nov 19. [Epub ahead of print].
57. Saleh AA, Gune US, Chaudhary RK, Turakhiya AP, Roy I. Roles of Hsp104 and trehalose in solubilisation of mutant huntingtin in heat shocked Saccharomyces cerevisiae cells. Biochim Biophys Acta 2014; 1843(4): 746-757.
58. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001; 24: 519-550.
59. Heiseke A, Aguib Y, Schatzl HM. Autophagy, prion infection and their mutual interactions. Curr Issues Mol Biol 2010; 12: 87-97.
60. Béranger F, Crozet C, Goldsborough A, Lehmann S. Trehalose impairs aggregation of PrPSc molecules and protects prion-infected cells against oxidative damage. Biochem Biophys Res Commun 2008; 374: 44-48.
61. Aguib Y, Heiseke A, Gilch S, et al. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 2009; 5: 361-369.
62. Ravits J, Appel S, Baloh RH, et al. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotem-poral Degener 2013; 14 Suppl 1: 5-18.
63. Maekawa S, Leigh PN, King A, et al. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathology 2009; 29: 672-683.
64. Rotunno MS, Bosco DA. An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. Front Cell Neurosci 2013; 7: 253.
65. Castillo K, Nassif M, Valenzuela V, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 2013; 9: 1308-1320.
66. Wang X, Fan H, Ying Z, Li B, Wang H, Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett 2010; 469: 112-116.
67. Zhang X, Chen S, Song L, et al. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy 2014; 10(4). [Epub ahead of print]
68. Brais B. Oculopharyngeal muscular dystrophy: a polyalanine my-opathy. Curr Neurol Neurosci Rep 2009; 9: 76-82.
69. Brais B. Oculopharyngeal muscular dystrophy. Handb Clin Neurol 2011; 101: 181-192.
70. Klein AF, Ebihara M, Alexander C, et al. PABPN1 polyalanine tract deletion and long expansions modify its aggregation pattern and expression. Exp Cell Res 2008; 314: 1652-1666.
71. Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet 2006; 15: 23-31.
72. Wada SI, Ohba SI, Someno T, Hatano M, Nomoto A. Structure and biological properties of lentztrehalose: a novel trehalose analog. J Antibiot (Tokyo) 2014; [Epub ahead of print].
73. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.
74. Takahashi S, Isaka M, Hamaishi M, et al. Trehalose protects against spinal cord ischemia in rabbits. J Vasc Surg 2013; pii: S0741-5214(13)01273-1.
75. Kara NZ, Toker L, Agam G, et al. Trehalose induced antidepres-sant-like effects and autophagy enhancement in mice. Psychopharmacology (Berl) 2013; 229: 367-375.